$60.65
+0.76%Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Acceptable margins but limited operational leverage. Operating expense control is important.
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
MMSI โข NASDAQ
| Merit Medical Systems, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
1.5B | 1.4B | 1.3B | 1.2B | 1.1B | 963.9M | 994.9M | 882.8M | 727.9M | 603.8M | 542.1M | 509.7M | 449M | 394.3M | 359.4M | 296.8M | 257.5M | 227.1M | 207.8M | 190.7M | |
GROSS PROFIT | ||||||||||||||||||||
(777.8M) | (713.2M) | (673.5M) | (631.9M) | (589.4M) | (562.7M) | (562.5M) | (488M) | (401.6M) | (338.8M) | (306.4M) | (284.5M) | (254.7M) | (212.3M) | (194M) | (168.3M) | (148.7M) | (133.9M) | (128M) | (117.6M) | |
736.9M | 643.3M | 583.9M | 519.1M | 485.3M | 401.2M | 432.4M | 394.8M | 326.3M | 265M | 235.8M | 225.2M | 194.4M | 182M | 165.5M | 128.5M | 108.8M | 93.3M | 79.8M | 73.1M | |
OPERATING INCOME | ||||||||||||||||||||
(552.6M) | (487.6M) | (458.7M) | (431.5M) | (424.4M) | (402.7M) | (416.9M) | (335.6M) | (280.5M) | (229.6M) | (197.2M) | (184.5M) | (162.5M) | (149.9M) | (126.4M) | (103M) | (76M) | (62.3M) | (56.8M) | (54.1M) | |
(455.2M) | (376.7M) | (373.7M) | (342.5M) | (335.7M) | (297.7M) | (327.3M) | (276M) | (229.1M) | (184.4M) | (156.3M) | (147.9M) | (128.6M) | (122.1M) | (104.5M) | (87.6M) | (64.8M) | (53.1M) | (48.1M) | (45.5M) | |
(97.4M) | (83.8M) | (82.7M) | (75.5M) | (71.2M) | (57.5M) | (65.6M) | (59.5M) | (51.4M) | (45.2M) | (40.8M) | (36.6M) | (33.9M) | (27.8M) | (21.9M) | (15.3M) | (11.2M) | (9.2M) | (8.7M) | (8.6M) | |
184.4M | 155.7M | 123.9M | 87.6M | 60.9M | -1.6M | 15.4M | 58.6M | 33.1M | 34.9M | 37.5M | 40.2M | 27.8M | 29.6M | 33.2M | 17.2M | 32.8M | 31M | 23M | 19M | |
PRE-TAX INCOME | ||||||||||||||||||||
(26.5M) | (31.2M) | (15.5M) | (6.3M) | (5.3M) | (10M) | (12.7M) | (10.4M) | (7.7M) | (8.8M) | (6.2M) | (8.8M) | (8M) | (604K) | (789K) | (596K) | (28K) | (17K) | (0.0) | (0.0) | |
-11.4M | -5M | -13.1M | -5.9M | -4.5M | -9.4M | -12.7M | -9.2M | -7.4M | -8.7M | -6M | -8.6M | -7.8M | -378K | -660K | -562K | 150K | 764K | 0.0 | 0.0 | |
(0.0) | (27.1M) | (3.5M) | (13.5M) | (17.5M) | (47.5M) | (24M) | (63K) | -872K | -773K | -386K | (18K) | -216K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-13.4M | -5.7M | -11.9M | -4.9M | -7M | -11.7M | -13.2M | -9.1M | 2.8M | -9.5M | -6.3M | -8.6M | -8M | -2M | -315K | -416K | 247K | 861K | 429K | 174K | |
170.9M | 150M | 112.1M | 82.6M | 53.9M | -13.2M | 2.2M | 49.5M | 35.9M | 25.4M | 31.2M | 31.6M | 19.8M | 27.6M | 32.9M | 16.8M | 33.1M | 31.8M | 23.4M | 19.2M | |
NET INCOME | ||||||||||||||||||||
(42.4M) | (29.6M) | (17.7M) | (8.1M) | (5.5M) | -3.4M | -3.3M | (7.5M) | (8.4M) | (5.3M) | (7.4M) | (8.6M) | (3.3M) | (7.9M) | (9.8M) | (4.3M) | (10.6M) | (11.1M) | (7.8M) | (6.9M) | |
128.5M | 120.4M | 94.4M | 74.5M | 48.5M | -9.8M | 5.5M | 42M | 27.5M | 20.1M | 23.8M | 23M | 16.6M | 19.7M | 23M | 12.5M | 22.5M | 20.7M | 15.6M | 12.3M |
MMSI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 19, 2026 | May 13, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 01, 2026 | April 01, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 31, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 04, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 |
Continue your MMSI research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.